Patent · US Active

Treatment prediction involving HMGCR

US8945832B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

Atlas Antibodies AB · SE

Inventors

Mathias Uhlen · Uppsala, SE
Fredrik Pontén · Uppsala, SE
Karin Jirström · Malmö, SE
Donal J. Brennan · Stranorlar, IE

Key dates

Filing date	Nov 16, 2010
Grant date	Feb 3, 2015
Priority date	—
Expiry date	Apr 17, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/90209
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.